A highly skilled team dedicated to develop drugs for neurological disorders

Yann GODFRIN, Ph.D.

Chief Executive Officer

20+ years of experience in management of Biopharmaceutical companies focused product development from bench to Phase III clinical trial. Dr Godfrin was co-Founder, former CEO and CSO of ERYTECH Pharma (EPA/NASDAQ: ERYP) and former CEO of Hemoxymed Europe. In addition to his entrepreurship, Dr Godfrin is an expert in pre-clinical and clinical product development strategy and has been consultant for several biopharmaceutical companies. He is the inventor of more than 15 patents families and several scientific publications. Dr Godfrin holds a Ph.D. degree in Health & Life Sciences (University of Nantes, France), an Engineer degree in Biomedical Sciences (University of Compiègne, France) and a Master degree in Pharmaceutical Drug Development (University of Lyon, France).

Valérie BOURDES, M.D., MPH

Chief Medical Officer

25+ years of experience in the drug development. First as Epidemiologist at WHO, Dr Bourdès. served as health economist at Merck KgaA. Then she joined the Neurological Hospital of Lyon to coordinate clinical studies in Multiple Sclerosis. Dr. Bourdès pursued her career as Medical Director at ICTA, Senior Global Medical Director Expert at Galderma  where she was Head of translational unit and then CNS Medical Director at Syneos Health. Dr. Bourdès has a strong expertise in the drug developement and especially in CNS diseases.

Luca BOLLIGER, Ph.D.

Chief Business Officer

20+ years of experience in the pharmaceutical industry. First as Global discovery portfolio manager at Hoffmann-La Roche Ltd. He then pursued his career in the financial industry as a Fundamental analyst at BT&T asset management. He established Biopolo Ticino before becoming Director Business Development at Actelion. Luca Bolliger joined Recordati from Novimmune where he is VP and Director Corporate Licensing.

Sébastien MARIE

Clinical Operations Director

15+ years of experience in clinical trial management. Prior to joining Axoltis Pharma, he served as Clinical Project Manager for a mid-size CRO, managing various full-service national and international projects with biotech and big/mid-size pharma companies, from regulatory submissions to clinical study report writing. He recently participated in the development of drugs in rare diseases, managing several partners in E.U. and in the USA. M. MARIE holds a Master Degree in Biology (University of Bourgogne, France), a Degree Specialized in Clinical Research (University of Caen, France) and certified in International Project Management (AFITEP, Paris).